The Most Important Hearing In Washington This Week – For Some Of Us, At Least

Impeachment? That’s nothing compared to the chance to hear publicly from Stephen Hahn about what kind of US FDA Commissioner he might be.

Stephen Hahn of MD Anderson Cancer Center is expected to be nominated for FDA commissioner
US FDA commissioner nominee Stephen Hahn, an executive at MD Anderson Cancer Center, will testify before the Senate HELP committee on Wednesday.

November 20 promises to be a blockbuster date in the US House of Representatives’ impeachment hearings, with Ambassador Gordon Sondland scheduled to testify publicly about what President Trump did or did not do to encourage the Ukraine to investigate a political rival.

That will be at best the second most interesting hearing for anyone interested in the future of the US Food...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

PS-AgencyLeadership (Premium-1): Study Reveals How Immune System of Astronauts Breaks Down

Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.

Nancy Test Circulable Section Geography

 

This is a short description

New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming

 

Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.

Califf: Not Wise To Create Problems Related to Chinese Pharma Supply Chain Dependence

 

The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.

More from Agency Leadership

New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming

 

Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.

Califf: Not Wise To Create Problems Related to Chinese Pharma Supply Chain Dependence

 

The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.